Poor outcome of patients with COVID-19 after CAR T-cell therapy for B-cell malignancies: results of a multicenter study on behalf of the European Society for Blood and Marrow Transplantation (EBMT) Infectious Diseases Working Party and the European Hematology Association (EHA) Lymphoma Group

Anne Mea Spanjaart, Per Ljungman, Rafael de La Camara, Gloria Tridello, Valentín Ortiz-Maldonado, Alvaro Urbano-Ispizua, Pere Barba, Mi Kwon, Dolores Caballero, Pierre Sesques, Emmanuel Bachy, Roberta Di Blasi, Catherine Thieblemont, Friso Calkoen, Pim Mutsaers, Johan Maertens, Livia Giannoni, Emma Nicholson, Matthew Collin, Carlos Pinho VazElisabetta Metafuni, Joaquin Martinez-Lopez, Fiona L. Dignan, Josep Maria Ribera, Arnon Nagler, Frantisek Folber, Robin Sanderson, Adrian Bloor, Fabio Ciceri, Nina Knelange, Francis Ayuk, Nicolaus Kroger, Marie José Kersten, Stephan Mielke*

*Corresponding author for this work

Research output: Contribution to journalArticleAcademicpeer-review

24 Citations (Scopus)
4 Downloads (Pure)
Original languageEnglish
Pages (from-to)3585-3588
Number of pages4
JournalLeukemia
Volume35
Issue number12
DOIs
Publication statusPublished - 8 Nov 2021

Bibliographical note

Funding Information:
There is no financial support for this work that could have influenced the outcomes described in the paper. However, particular authors report a potential competing interests, which is described below. VOM has received compensation for travel support from Kite/Gilead, Novartis, BMS/Celgene, Takeda and Janssen and consultant or advisory fees from Kite/Gilead, Novartis, BMS/Celgene and compensation for presentations from Kite/Gilead. PB has received honoraria from Amgen, BMS, Gilead, Incyte, Miltenyi Biotec, Novartis and Pfizer and funding from the Carlos III Health Institute FIS16/01433 and 20/00197, Asociación Española contra el Cáncer (Ideas Semilla 2019) and a PERIS 2018-2020 grant from the Generalitat de Catalunya (BDNS357800). MK has received consultancy fees and honoraria from Novartis, BMS/ Cellgene, Kite/Gilead, and Pfizer. PS has received honoraria from Kite/Gilead, Novartis, and Chugai. RDB has received honoraria/hospitality from Gilead, Novartis, and Janssen. CT has received consultancy fees, advisory fees and honoraria from Novartis, BMS/Celgene, Roche, Janssen, Takeda, Kite/Gilead, Incyte and research funding from Roche and travel expenses from Novartis, BMS/Celgene, Roche, Janssen, Kite/Gilead. PM has received research funding from Astra Zeneca and consultancy fees from BMS/ Celgene. EN has received research funding from Kite/Gilead, advisory board fees for Novartis and BMS/Celgene, travel support from Novartis and Kite/Gilead, speaker fees from Kite/Gilead. JML has received consultancy fees from Janssen, BMS, Novartis, Incyte, Roche, GSK and Pfizer and research funding from Roche, Novartis, Incyte, Astellas, and BMS. JMR received consultancy and speaker fees from Pfizer, Amgen, Shire, Ariad, Takeda and Novartis and research funding from Phizer, Amgen, Ariad, and Takeda. RS has received speakers fees and honoraria from Kite/Gilead and Novartis. AB has received honoraria from Kite/Gilead and Novartis. FA has received research funding from Mallinckrodt/ThekarosHonoraria from Novartis, BMS/Celgene, Janssen, Takeda, Mallinckrodt/Thekaros, Kite/Gilead, and Miltenyi Biomedicine. NK has received a research grant and honoraria from Novartis, Kite/Gilead, and BMS. SM has received funding from Celgene/BMS: Speakers bureau (via my institution); Novartis: Speakers bureau (via my institution); Gilead/Kite: Other: Travel support, Expert panel (via my institution); DNA Prime SA and funding from Speakers bureau (via my institution); Miltenyi: Other: Data safety monitoring board (via my institution) Immunicum: Other: Data safety monitoring board (via my institution). MJK has received research funding from Kite/Gilead and compensation for advisory boards and presentations and/or travel support from Kite/Gilead, Novartis, BMS/Celgene, and Miltenyi Biotec (to institution).

Cite this